1 / 4

Promising New Cancer Drugs Jan 2024

Medtech Monday: Bullish Bets on Breakthroughs - Examining Cutting-Edge Trials and Investment Opportunities Attention all healthcare and biotech investors! Buckle up for a deep dive into the hottest clinical trials poised to shape the future of medicine in 2024 and beyond. To get a detailed report, contact us at - info@insights10.com, visit - https://bit.ly/3uGcvZW

Insights4
Download Presentation

Promising New Cancer Drugs Jan 2024

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Promising New Cancer Drugs (Jan 2024)

  2. Manufacturer Name Phase (Jan 2024) Molecule Brand Name ATR inhibitor+ PDL-1 mAb Ceralasertib + Imfinzi Phase III, expected filing in 2024 PD-1/CTLA-4 bispecific mAb Phase III, newto thisphase Volrustomig STING Agonist TAK-500 Phase III BTK inhibitor+ R-CHOP Calquence + R-CHOP Phase II Source: FDA

  3. Manufacturer Name Phase (Jan 2024) Molecule Brand Name BTK inhibitor+ BCL-2 inhibitor+ anti-CD20 mAb Calquence +venetoclax+ obinutuzumab Phase II CD27 agonist mAb Boserolimab Phase II, in combination with KEYTRUDA Targeted Next Generation Interferon Modakafusp Alfa Phase II EGFR x CD3 Conditional T- cell engager TAK-186 Phase II Source: FDA

  4. Manufacturer Name Phase (Jan 2024) Molecule Brand Name Subasumstat(TAK-981) SUMOylation Inhibitor Phase II Anaplastic Lymphoma Kinase (ALK) inhibitor Brigatinib Phase II mobocertinib EGFR/HER2 inhibitor Phase II Source: FDA

More Related